– USA, MD – Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of John Jacobs to its Board of Directors as President and CEO, to succeed Stan Erck effective as of January 23, 2023.
“John is a seasoned industry leader who will bring a fresh perspective and deep industry expertise to Novavax,” said Board Chairman, Dr. Jim Young.
About John C. Jacobs
Mr. Jacobs brings over 25 years of commercial, operations, business, and leadership experience across multiple therapeutic areas. He will join Novavax from Harmony Biosciences, where he has served as President and CEO and a member of the Board of Directors since June 2018, and EVP and CCO from October 2017 to June 2018. Notably, Mr. Jacobs led the company through a successful IPO and conducted its first product through FDA review, approval, and commercialization. Before joining Harmony, Mr. Jacobs held leadership roles at Teva Pharmaceuticals beginning in 2014, including SVP and GM of the Respiratory Business Unit, SVP of Commercial Operations in North America, and GM of Teva in Canada. Mr. Jacobs has also held positions of increasing scope and responsibility at major pharmaceutical companies including Cephalon, Wyeth, and Pfizer.
“I am grateful to Stan for the foundation that he has built and is honored to join Novavax in advancing its important global and public health mission,” said Mr. Jacobs. “I look forward to working with the team and helping to build on the accomplishments and business foundation that have been established over the past several years.”
He received a B.S. in business from the State University of New York College at Plattsburgh and an MBA from The State University of New York at Binghamton.
About Novavax
Novavax, Inc. is a biotechnology company that promotes improved health globally by discovering, developing, and commercializing innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine has received global authorization from multiple regulatory authorities, including the U.S. Food and Drug Administration, the European Commission, and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating its COVID-19-Influenza Combination (CIC) vaccine candidate, its quadrivalent influenza investigational vaccine candidate, and an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
